At a glance
Ruthenium-106 plaque for thick posterior uveal melanoma
Kaiserman et al examined effectiveness and safety of Ruthenium-106 brachytherapy in the management of thick posterior uveal melanoma (apical height >8.0 mm). 63 patients treated with brachytherapy were compared with 63 patients treated with enucleation. The 5- and 10-year all-cause mortality and melanoma-related mortality was comparable between the groups. Of the eyes that were initially treated with brachytherapy, 71% were saved from enucleation. Complications of brachytherapy included tumour regrowth (n = 15), scleral melt (n = 3), neovascular glaucoma (n = 5) and vitreous haemorrhage (n = 3). However, no significant difference in survival was noted between patients with and without local recurrence. The authors conclude that Ruthenium-106 brachytherapy is an alternative to enucleation in selected patients with thick posterior uveal melanoma.
See pages 1167
Conjunctival characteristics in POAG: in vivo confocal microscopy study
Ciancaglini et al evaluated bulbar conjunctiva with in vivo confocal microscopy (IVCM; HRT II Rostock Cornea Module) in 15 POAG patients undergoing trabeculectomy and 10 patients on medical therapy. Eyes were examined …
